[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 361
Citations 0
Invited Commentary
July 23, 2020

The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer

Author Affiliations
  • 1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 3Department of Radiation Oncology, Experimental Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA Oncol. Published online July 23, 2020. doi:10.1001/jamaoncol.2020.1793

Historically, patients with metastatic disease may undergo palliative low-dose radiotherapy for bleeding, pain, or other symptom control from localized progression of disease. However, the advent of increasingly effective systemic therapies has led to interest in exploring how consolidative high-dose locoregional therapies can prolong beneficial effects from systemic therapy in metastatic disease. Investigators have explored local therapy directed at metastatic foci in addition to treatment of in situ primary tumors. In oligometastatic cancers, for patients who did not progress with systemic therapy, the addition of local therapy directed at metastasis has demonstrated an improvement to overall survival (OS) compared with systemic therapy alone in early randomized studies.1,2 In low-volume metastatic prostate cancer, the addition of primary-directed radiotherapy has also improved OS.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words